EP Patent

EP1047418B1 — Inhibition of raf kinase using substituted heterocyclic ureas

Assigned to Bayer Pharmaceuticals Corp · Expires 2005-07-27 · 21y expired

What this patent protects

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

USPTO Abstract

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP1047418B1
Jurisdiction: EP
Classification: —
Expires: 2005-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.